NCT00023621已完成2 期
A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 3
- 主要终点
- Prevention of the development of basal cell carcinoma
研究概览
简要总结
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib may be an effective way to prevent the development of basal cell carcinoma.
PURPOSE: Randomized phase II trial to determine the effectiveness of celecoxib in preventing basal cell carcinoma in patients who have basal cell nevus syndrome.
详细描述
OBJECTIVES:
- Determine whether celecoxib prevents the development of basal cell carcinoma in patients with basal cell nevus syndrome.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 arms.
- Arm I: Patients receive oral celecoxib twice daily.
- Arm II: Patients receive oral placebo twice daily. Treatment continues for 2 years in the absence of unacceptable toxicity.
Patients are followed every 3 months for 3 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Prevention of the development of basal cell carcinoma
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Celecoxib in Treating Patients With Precancerous Lesions of the MouthHead and Neck CancerNCT00014404Memorial Sloan Kettering Cancer Center
已完成
2 期
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic KeratosisNon-melanomatous Skin CancerPrecancerous/Nonmalignant ConditionNCT00021294University of Arizona
撤回
2 期
Celecoxib in Preventing Skin Cancer in Patients With Actinic KeratosesPrecancerous ConditionNCT00027976University of Alabama at Birmingham
已完成
2 期
Eflornithine in Treating Patients At High Risk of Developing Prostate CancerProstate CancerNCT00006101Thomas E. Ahlering76
已完成
2 期
Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck CancerHead and Neck CancerNCT00064298Wake Forest University Health Sciences134